Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Immunology

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Christian Blank, Ian Brown, Amy C. Peterson, Mike Spiotto, Yoshiko Iwai, Tasuku Honjo and Thomas F. Gajewski
Christian Blank
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy C. Peterson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Spiotto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiko Iwai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tasuku Honjo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas F. Gajewski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-03-3259 Published February 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Flow cytometric analysis of B16.SIY cells. A−D, B16.SIY tumor cells were cultured in the presence (solid black) or absence (solid gray) of 20 ng/ml murine IFN-γ for 48 h and stained as indicated. A, analysis for green fluorescent protein expression of B16.SIY or B16.SIY-IFN and B16-F10 as negative control (black line). B, analysis of Kb expression. Control immunoglobulin staining is represented by the black line. C, analysis of PD-L1 expression. Control immunoglobulin staining is represented by the black line. D, analysis of PD-L2 expression. Control immunoglobulin staining is represented by the black line. E, positive control of PD-L2 expression on J558-B7DC transfectants (solid black), J558-neo (solid gray), and control immunoglobulin (black line).

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Markedly improved 2C effector function in the absence of PD-1. A, cytolytic activity. Primed 2C/RAG2−/− or 2C/RAG2−/−/PD-1−/− T cells were cocultured with B16.C-IFN or B16-SIY-IFN (48 h IFN-γ pretreatment) for 4 h at the indicated E:T cell ratios, and lytic function was determined by 51Cr release. The difference between wild-type and PD-1−/− 2C cells was significant using an unpaired t test (P < 0.001). B and C, cytokine production. Primed 2C/RAG2−/− or 2C/RAG2−/−/PD-1−/− T cells were stimulated with B16.SIY or B16.SIY-IFN cells, and supernatants were collected after 18 h. Levels of IL-2 (B) and IFN-γ (C) were determined by ELISA. Tumors alone indicates cytokine levels detected without T cells. Medium indicates cytokine levels detected with T cells alone. Similar results were observed in at least three experiments.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Improved tumor cell elimination in vitro by PD-1-deficient 2C cells. Equal numbers of primed 2C/RAG2−/− T cells (A and B) or 2C/RAG−/−/PD-1−/− cells (C) were cocultured with B16.SIY (A) or IFN-γ-pretreated B16-SIY (B and C) in 24-well plates. Areas representative of the cell density were photographed at day 3. Similar results were found on days 4 and 5 and in at least three experiments (data not shown).

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    A, PD-1 expression on 2C T cells during priming. Purified 2C/RAG2−/− (top row) and 2C/RAG−/−/PD-1−/− (bottom row) T cells were primed with mitomycin C-treated P815.B71, stained with FITC anti-PD-1, and analyzed by flow cytometry at the indicated time points. At day 4, the cells were collected, purified by Ficoll-Hypaque centrifugation, reprimed for another 4 days, and analyzed similarly. B, PD-L1 expression by 2C T cells. Purified 2C/RAG2−/− (top row) and 2C/RAG−/−/PD-1−/− (bottom row) T cells were primed with mitomycin C-treated P815.B71 and stained for PE PD-L1 on day 0 (left panels) and day 2 (right panels). C, augmentation of T-cell activation with anti-PD-L1 antibody during the effector phase but not the priming phase. Purified 2C/RAG2−/− cells were primed for 4 days and reprimed for 4 days with mitomycin C-treated P815.B71 in the absence or presence of anti-PD-L1 mAb or control immunoglobulin. At day 8, cells were collected, purified by Focoll-Hypaque centrifugation, and stimulated with B16.SIY-IFN (left panel). Control primed 2C cells were also stimulated in the presence of anti-PD-L1 mAb or control immunoglobulin (right panel). After 18 h, supernatants were collected, and levels of interleukin 2 were determined by ELISA. Similar results were seen for IFN-γ (data not shown) and in two independent experiments.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    A, PD-L1 expression on murine tumor cell lines. The indicated tumor cell lines were cultured in complete medium with 10% FCS in the absence (solid gray) or presence (solid black) of 20 ng/ml murine IFN-γ for 48 h, stained with PE-anti-PD-L1, and analyzed by flow cytometry. Isotype control antibody staining was performed in parallel (black line). No expression of PD-L2 was observed on any tumor cell line (data not shown). Similar results were observed in at least two experiments. B and C, PD-L1 expression on human melanoma cell lines. The indicated tumor cell lines were cultured in complete medium with 10% FCS in the absence or presence of 200 ng/ml human IFN-γ for 48 h, stained with PE-antihuman PD-L1, and analyzed by flow cytometry. Isotype control antibody staining was performed in parallel. Representative flow cytometry histogram of SKMel28, showing control immunoglobulin staining (black line) and PE PD-L1 without (solid gray) or with (solid black) pretreatment with IFN-γ, is shown in B. Changes of mean fluorescence intensity of all tumor lines analyzed are shown in C. Similar results were observed in at least two experiments.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Increased proliferation of primed 2C/RAG2−/−PD-1−/− T cells in response to B16.SIY-IFN or HTR.C tumor cells. Purified primed 2C/RAG2−/− ( Embedded Image) and 2C/RAG−/−/PD-1−/− (▪) cells were stimulated with either mitomycin C-treated B16.SIY-IFN (A) or HTR.C (B) cells or a 5:1 ratio of anti-CD3:anti-CD28-coated beads for 48 h. [3H]Thymidine was added during the last 6 h, and incorporated radioactivity was measured. Similar results were observed in at least two experiments.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Absence of PD-1 enables 2C T cells to reject HTR.C tumors in vivo. Groups of 4–10 of P14/RAG2−/− mice were challenged s.c. with 106 HTR.C cells after i.v. adoptive transfer of 106 naive 2C/RAG2−/− (•), 2C/RAG2−/−/CTLA-4−/− (▴), or 2C/RAG2−/−/PD-1−/− T cells (▪) 24 h earlier. PBS-injected mice were compared as a control (○). Mean diameters were determined at the indicated time points. The numbers of animals ultimately rejecting the tumor are shown to the right of each curve. The data are pooled from two experiments.

PreviousNext
Back to top
Cancer Research: 64 (3)
February 2004
Volume 64, Issue 3
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
Christian Blank, Ian Brown, Amy C. Peterson, Mike Spiotto, Yoshiko Iwai, Tasuku Honjo and Thomas F. Gajewski
Cancer Res February 1 2004 (64) (3) 1140-1145; DOI: 10.1158/0008-5472.CAN-03-3259

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
Christian Blank, Ian Brown, Amy C. Peterson, Mike Spiotto, Yoshiko Iwai, Tasuku Honjo and Thomas F. Gajewski
Cancer Res February 1 2004 (64) (3) 1140-1145; DOI: 10.1158/0008-5472.CAN-03-3259
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Abstract 6644: A comprehensive in vitro and in vivo system to evaluate STING agonist efficacy in cancer therapeutics
  • Abstract 6686: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
  • Abstract 6678: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy
Show more Immunology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement